NICE recommends Revlimid for newly diagnosed multiple myeloma patients
Cost-effectiveness agency initially turned down the drug in this setting
Read More
Tag: Revlimid
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read More
Revlimid gets NICE nod for lymphoma
The decision brings a new option to the market for around 900 patients.
Read More
NICE recommends Revlimid as multiple myeloma alternative
The new indication will benefit approximately 2,100 patients.
Read More
Revlimid boosts survival in myeloma patients post-transplant
Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
Read More
FDA puts on hold Keytruda studies
US regulators have placed on clinical hold three studies testing the immunotherapy Keytruda in combination with other therapies for multiple myeloma because of patient deaths.
Read More
Myeloma UK launches ‘world first’ immunotherapy trial
Myeloma UK has launched a ground-breaking immunotherapy trial which aims to modulate the immune system to target myeloma.
Read More
EU expands use of Revlimid to include post ACST use
European regulators have expanded the scope of Celgene’s Revlimid to include its use as monotherapy for the maintenance treatment of adults with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
Read More
‘Extraordinary growth’ on the cards for cancer immunotherapies
The market for cancer immunotherapies is set to swell more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, with a rapid compound annual growth rate of 23.9 percent, predicts business intelligence provider GBI Research.
Read More
NICE rejects earlier use of multiple myeloma drugs
Patients with multiple myeloma are being barred from routine access on the NHS to Celgene’s Revlimid and Amgen’s Kyprolis in the second-line setting.
Read More
Wales endorses NHS use of Celgene’s Revlimid
Around 300 patients with multiple myeloma in Wales will get National Health Service access to treatment with Celgene’s Revlimid after the drug was recommended for first-line use by cost regulators.
Read More
Celgene’s Revlimid approved for Mantle Cell Lymphoma
Celgene’s Revlimid has been approved by European regulators to treat patients with relapsed/refractory Mantle Cell Lymphoma (MCL), a rare sub-type of aggressive non-Hodgkin’s lymphoma (NHL).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
